| Product Unit Size | Cost | Quantity | Stock |
|---|
Trimebutine exhibits antibacterial and gastrointestinal motility modulating activities; it is clinically used to treat irritable bowel syndrome (IBS). Trimebutine displays antibiotic activity against Escherichia and Pseudomonas. This compound enhances gastrointestinal muscle contractions by inhibiting L-type Ca2+ channels and decreasing Ca2+-sensitive BK K+ currents and may also act as an agonist at opioid receptors.
| Cas No. | 34140-59-5 |
|---|---|
| Purity | ≥96% |
| Formula | C22H29NO5 • C4H4O4 |
| Formula Wt. | 503.54 |
| Chemical Name | 3,4,5-Trimethoxybenzoic acid 2-(dimethylamino)- 2-phenylbutyl ester maleate |
| IUPAC Name | (Z)-but-2-enedioic acid;[2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate |
| Synonym | Cerekinon, Debridat, Digerent, Foldox, Polibutin, Spabucol, Trimedat |
| Melting Point | 105-106°C |
| Solubility | Slightly soluble in chloroform, methanol. Soluble in water (35 mg/mL), ethanol, DMSO. |
| Appearance | White Crystal Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Kountouras J, Sofianou D, Gavalas E, et al. Trimebutine as a potential antimicrobial agent: a preliminary in vitro approach. Hippokratia. 2012 Oct;16(4):347-9. PMID: 23935315.
Tan W, Zhang H, Luo HS, et al. Effects of trimebutine maleate on colonic motility through Ca²+-activated K+ channels and L-type Ca²+ channels. Arch Pharm Res. 2011 Jun;34(6):979-85. PMID: 21725819.
